Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;43(2):145-51.
doi: 10.1007/s15010-015-0749-y. Epub 2015 Feb 21.

Novel antibiotics: are we still in the pre-post-antibiotic era?

R Draenert  1 , U Seybold, E Grützner, J R Bogner
Affiliations
Review

Novel antibiotics: are we still in the pre-post-antibiotic era?

R Draenert et al. Infection. 2015 Apr.

Abstract

Purpose: Therapeutic efficacy and safety in infections due to multidrug-resistant bacteria can be improved by the clinical development of new compounds and devising new derivatives of already useful antibiotics. Due to a striking global increase in multidrug-resistant Gram-positive but even more Gram-negative organisms, new antibiotics are urgently needed.

Methods: This paper provides a review of novel antibiotic compounds which are already in clinical development, mainly in phase III clinical trials.

Conclusion: Each of these new trials increases the possibility of new antibiotics receiving approval.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic antibiotic action: new compounds in an overview
See this image and copyright information in PMC

References

    1. Dalhoff A. Resistance surveillance studies: a multifaceted problem—the fluoroquinolone example. Infection. 2012;40:239–262. doi: 10.1007/s15010-012-0257-2. - DOI - PubMed
    1. Lubbert C, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case–control analysis. Infection. 2014;42:309–316. doi: 10.1007/s15010-013-0547-3. - DOI - PubMed
    1. Zhanel GG, Schweizer F, Karlowsky JA. Oritavancin: mechanism of action. Clin Infect Dis. 2012;54:S214–S219. doi: 10.1093/cid/cir920. - DOI - PubMed
    1. Rubino CM, et al. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53:4422–4428. doi: 10.1128/AAC.00231-09. - DOI - PMC - PubMed
    1. Belley A, et al. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother. 2013;57:205–211. doi: 10.1128/AAC.01428-12. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources